TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06574126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
Description: In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion
Description: In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
Study: NCT05735184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration
Study: NCT06425523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EUC)
Description: The Enhanced Usual Care (EUC) control condition involves a single 15-minute psychoeducation session providing information on managing overthinking and utilizing available mental health services in the settlement. These services include psychosocial support from community health workers and clinical mental health services (counseling and medications) provided weekly at local primary care centers by a visiting team.
Study: NCT06385028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: The intervention will be delivered through a phone application: each week, the participant will define a new daily step goal for the following week. Then he/she will receive daily notifications (except Sundays) about physical activity, sedentary behavior and their consequences on general health and osteoarthritis specifically. These notifications are designed to promote physical activity in this specific population.
Study: NCT06067425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Solution for injection; Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Solution for injection; Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Solution for injection; Subcutaneous injection
Study: NCT05938270

Intervention type: DRUG
Group type: OTHER
Intervention: Saruparib (AZD5305)
Description: Saruparib (AZD5305) given orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Saruparib (AZD5305)
Description: Saruparib (AZD5305) given orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Darolutamide
Description: Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg

Intervention type: DRUG
Group type: OTHER
Intervention: Darolutamide
Description: Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg

Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
Study: NCT05350774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline 250ml for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin
Description: IVIg - IV immunoglobulin 0.4g/kg/day for 5 days
Study: NCT04704648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical
Description: The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency.
Study: NCT05244239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo RT
Study: NCT06137118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: Investigational Product administered via intravenous infusion.
Study: NCT05443165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The effectiveness of the online decision support system developed for symptom self-management
Description: The online decision support system will appear with mild, moderate, or high severity according to symptom severity. If the patient's symptom is of mild category severity, a green area will appear on the screen and patients will see information on self-management strategies in this area. If patient's symptom is of moderate category severity, a yellow area will appear on the screen and patients will see information on self-management strategies and symptom monitoring at home in this area. In moderate symptom severity, when a yellow area occurs, patients should be asked, Is your fever above 38℃? according to their needs. Information about the treatment steps to be followed will be given. If the patient's symptom is in a severe category, a red area will appear on the screen and the patients will be warned to apply to the healthcare institution within this area.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom self-management with an education booklet
Description: Symptom frequency and severity level of NHL patients will be evaluated with an online web-based application. NHL patients, who will be treated with the symptom self-management with education booklet. Participants will be asked to evaluate the frequency and severity of symptoms through the online symptom evaluation system on the 3rd, 7th, and 10th days of the 3rd, 4th, and 5th chemotherapy courses for three months. They will be able to do symptom self-management within the scope of the patient education booklet sent to them via SMS.
Study: NCT05683041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier
Description: Hyalobarrier is a viscous, transparent gel and is used as a preventive measure for post-operative adhesions in the abdominal and uterine cavity.
Study: NCT05735184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration
Study: NCT05924165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Oxycodone, Q6 PRN
Description: Oxycodone is an opioid that is used to relieve moderate to severe pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Ketorolac, Q6 PRN
Description: Ketorolac is an NSAID used to relieve moderately severe pain.
Study: NCT06120283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Planned doses administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Planned doses administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Standard dose administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Standard dose administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Standard dose administered orally as a tablet.
Study: NCT06502717

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study: NCT06205420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable composite resin restoration
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable giomer restoration
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Study: NCT02438202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thymatron IV device (Somatics)
Description: Patients will be treated with a modified routine ECT/maintenance ECT series.
Study: NCT05861986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Study: NCT05544136

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FMISO PET/CT scan
Description: 18F-FMISO PET/CT scan (only 1 injection) that occurs 5-10 treatment days after RT start

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Description: * 18F-FMISO hypoxia negative patients complete CRT with 70Gy primary tumor and 50Gy de-escalated RT dose to gross nodes (if 50Gy is has pilot efficacy, then 44Gy to gross nodes; if 44Gy has pilot efficacy, then 40Gy to gross nodes).~* 18F-FMISO hypoxia positive patients are taken off study and complete SOC 70Gy CRT to primary tumor and gross nodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The chemotherapy used in this protocol is the standard of care for head and neck cancer, cisplatin or carboplatin/5-Fluorouracil
Study: NCT06300307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-01
Description: Solution for infusion
Study: NCT05735184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous or Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous Administration
Study: NCT06300307

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study: NCT06503146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FAPI-74
Description: Participants will receive a single intravenous (IV) dose of \[18F\]FAPI-74 prior to PET/CT imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FDG
Description: 18F-FDG PET/CT or PET/MRI imaging will be done per standard of care.
Study: NCT06303193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: Pacritinib will be administered orally on a continuous basis for 28 day cycles without a rest period between cycles. Dose assigned by dose level/phase.
Study: NCT06580106

Intervention type: OTHER
Intervention: Biospecimen samples
Description: Buccal swabs and Blood samples will be collected throughout study.
Study: NCT06179160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB161734
Description: INCB161734 will be administered at protocol defined dose.
Study: NCT06597591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR headset
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: 8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
Study: NCT06223633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PK Papyrus Covered Coronary Stent System
Description: PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
Study: NCT06694155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Crossover
Description: This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 week of Non-whey protein Placebo supplement
Study: NCT05931406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: A normal working day from of 12h

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: A normal working day from of 12h

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-and-stand desk
Description: a working day during which the participants have to get up at least 5 min/hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-and-stand desk
Description: a working day during which the participants have to get up at least 5 min/hour
Study: NCT05931406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycloergometer
Description: a working day during which they can use a cycloergometer installed under the desk

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycloergometer
Description: a working day during which they can use a cycloergometer installed under the desk